Analysts: Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) Stock Could Go to 221.00

Analysts are weighing in on how Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) , might perform in the near term. Wall Street analysts have a  assessment of the stock, with a mean rating of 2.0. The stock is rated as buy by 6 analysts, with 7 outperform and 7 hold rating. The rating score is on a scale of 1 to 5 where 1 stands for strong buy and 5 stands for strong sell.

For the current quarter, the 19.00 analysts offering adjusted EPS forecast have a consensus estimate of $1.18 a share, which would compare with $1.44 in the same quarter last year. They have a high estimate of $1.29 and a low estimate of $1.14. Revenue for the period is expected to total nearly $742.51M from $636.21M the year-ago period.

For the full year, 20.00 Wall Street analysts forecast this company would deliver earnings of 5.06 per share, with a high estimate of $5.18 and a low estimate of $4.99. It had reported earnings per share of $4.99 in the corresponding quarter of the previous year. Revenue for the period is expected to total nearly $3.06B versus 2.60B in the preceding year.

The analysts project the company to maintain annual growth of around 20.34% percent over the next five years as compared to an average growth rate of 16.51% percent expected for its competitors in the same industry.

Among the 18 analysts Data provided by Thomson/First Call tracks, the 12-month average price target for ALXN is $187.61 but some analysts are projecting the price to go as high as $221.00. If the optimistic analysts are correct, that represents a 79 percent upside potential from the recent closing price of $123.57. Some sell-side analysts, particularly the bearish ones, have called for $145.00 price targets on shares of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) .

In the last reported results, the company reported earnings of $1.44 per share, while analysts were calling for share earnings of $1.38. It was an earnings surprise of 4.30%percent. In the matter of earnings surprises, the term Cockroach Effect is often implied. Cockroach Effect is a market theory that suggests that when a company reveals bad news to the public, there may be many more related negative events that have yet to be revealed. In the case of earnings surprises, if a company is suggesting a negative earnings surprise it means there are more to come.

Alexion Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes life-transforming therapeutic products. The company offers Soliris (eculizumab), a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; and atypical hemolytic uremic syndrome (aHUS), a genetic disease. It provides Strensiq (asfotase alfa), a targeted enzyme replacement therapy for patients with hypophosphatasia (HPP); and Kanuma (sebelipase alfa) for the treatment of patients with lysosomal acid lipase deficiency. The company also conducts Phase IV clinical trials on Soliris for the treatment of PNH registry; Phase III clinical trials for the treatment of myasthenia gravis, neuromyelitis optica spectrum disorder, and delayed kidney transplant graft function; and Phase II clinical trials for antibody mediated rejection in presensitized renal transplant patients. It develops cPMP (ALXN 1101) that is in Phase II/III trial for treating metabolic disorders; and ALXN 1007, a novel humanized antibody in Phase II clinical trial for the treatment of anti-phospholipid syndrome and graft versus host disease. The company serves distributors, pharmacies, hospitals, hospital buying groups, and other health care providers, as well as governments and government agencies in the United States, Europe, the Asia Pacific, and internationally. Alexion Pharmaceuticals, Inc. has agreements with X-Chem Pharmaceuticals (X-Chem) to identify novel drug candidates from X-Chem’s proprietary drug discovery engine; Moderna Therapeutics, Inc. (Moderna) that provides the option to purchase drug products for clinical development commercialization of Moderna’s messenger RNA therapeutics to treat rare diseases; and Ensemble Therapeutics Corporation for the identification, development, and commercialization of therapeutic candidates based on specific drug targets. The company was founded in 1992 and is headquartered in New Haven, Connecticut.

Analysts: American Express Company (AXP)

Analysts are weighing in on how American Express Company (NYSE:AXP), might perform in the near term. Wall Street analysts have a much less favorable assessment of the stock, with a mean rating of 2.8. The stock is rated as buy by 3 analysts, with 4 outperform and 21 hold rating. The rating score is on a scale of 1 to 5 where 1 stands for strong buy and 5 stands for strong sell.

For the current quarter, the 24.00 analysts offering adjusted EPS forecast have a consensus estimate of $1.93 a share, which would compare with $1.42 in the same quarter last year. They have a high estimate of $2.28 and a low estimate of $1.50. Revenue for the period is expected to total nearly $8.33B from $8.28B the year-ago period.

For the full year, 22.00 Wall Street analysts forecast this company would deliver earnings of 5.56 per share, with a high estimate of $6.16 and a low estimate of $5.16. It had reported earnings per share of $5.38 in the corresponding quarter of the previous year. Revenue for the period is expected to total nearly $32.04B versus 32.82B in the preceding year.

The analysts project the company to maintain annual growth of around 8.34% percent over the next five years as compared to an average growth rate of 10.88% percent expected for its competitors in the same industry.

Among the 23 analysts Data provided by Thomson/First Call tracks, the 12-month average price target for AXP is $67.91 but some analysts are projecting the price to go as high as $80.00. If the optimistic analysts are correct, that represents a 26 percent upside potential from the recent closing price of $63.25. Some sell-side analysts, particularly the bearish ones, have called for $56.00 price targets on shares of American Express Company (NYSE:AXP).

In the last reported results, the company reported earnings of $1.42 per share, while analysts were calling for share earnings of $1.32. It was an earnings surprise of 7.60%percent. In the matter of earnings surprises, the term Cockroach Effect is often implied. Cockroach Effect is a market theory that suggests that when a company reveals bad news to the public, there may be many more related negative events that have yet to be revealed. In the case of earnings surprises, if a company is suggesting a negative earnings surprise it means there are more to come.

American Express Company, together with its subsidiaries, provides charge and credit payment card products and travel-related services to consumers and businesses worldwide. It operates through four segments: U.S. Card Services, International Card Services, Global Commercial Services, and Global Network & Merchant Services. The companys products and services include charge and credit card products; network services; expense management products and services; travel-related services; and stored value/prepaid products. Its products and services also comprise merchant acquisition and processing, servicing and settlement, merchant financing, point-of-sale, and marketing and information products and services for merchants; fraud prevention services; and the design of customized customer loyalty and rewards programs. The company sells its products and services to consumers, small businesses, mid-sized companies, and large corporations through direct mail, online applications, in-house and third-party sales forces, and direct response advertising. American Express Company was founded in 1850 and is headquartered in New York, New York.

Analysts: Amgen, Inc. (NASDAQ:AMGN)

Analysts are weighing in on how Amgen, Inc. (NASDAQ:AMGN) , might perform in the near term. Wall Street analysts have a much less favorable assessment of the stock, with a mean rating of 2.4. The stock is rated as buy by 9 analysts, with 2 outperform and 10 hold rating. The rating score is on a scale of 1 to 5 where 1 stands for strong buy and 5 stands for strong sell.

For the current quarter, the 19.00 analysts offering adjusted EPS forecast have a consensus estimate of $2.74 a share, which would compare with $2.57 in the same quarter last year. They have a high estimate of $3.02 and a low estimate of $2.52. Revenue for the period is expected to total nearly $5.58B from $5.37B the year-ago period.

For the full year, 22.00 Wall Street analysts forecast this company would deliver earnings of 11.13 per share, with a high estimate of $12.21 and a low estimate of $10.71. It had reported earnings per share of $10.38 in the corresponding quarter of the previous year. Revenue for the period is expected to total nearly $22.53B versus 21.66B in the preceding year.

The analysts project the company to maintain annual growth of around 8.37% percent over the next five years as compared to an average growth rate of 25.76% percent expected for its competitors in the same industry.

Among the 16 analysts Data provided by Thomson/First Call tracks, the 12-month average price target for AMGN is $185.31 but some analysts are projecting the price to go as high as $206.00. If the optimistic analysts are correct, that represents a 35 percent upside potential from the recent closing price of $152.27. Some sell-side analysts, particularly the bearish ones, have called for $157.00 price targets on shares of Amgen, Inc. (NASDAQ:AMGN) .

In the last reported results, the company reported earnings of $2.57 per share, while analysts were calling for share earnings of $2.43. It was an earnings surprise of 5.80%percent. In the matter of earnings surprises, the term Cockroach Effect is often implied. Cockroach Effect is a market theory that suggests that when a company reveals bad news to the public, there may be many more related negative events that have yet to be revealed. In the case of earnings surprises, if a company is suggesting a negative earnings surprise it means there are more to come.

Amgen Inc., a biotechnology company, engages in discovering, developing, manufacturing, and delivering human therapeutics worldwide. It offers products for the treatment of illness in the areas of oncology/hematology, cardiovascular, inflammation, bone health, nephrology, and neuroscience. The companys principal products include Neulasta, a pegylated protein to decrease the incidence of infection associated with chemotherapy-induced febrile neutropenia in cancer patients; NEUPOGEN, a recombinant-methionyl human granulocyte colony-stimulating factor for reducing the incidence of infection for patients with non-myeloid malignancies; and Enbrel to treat rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis. Its principal products also comprise EPOGEN to treat a lower-than-normal number of red blood cells caused by chronic kidney disease (CKD) in patients on dialysis; Aranesp for treating anemia; XGEVA for the prevention of skeletal-related events; Prolia to treat postmenopausal women with osteoporosis; Repatha for the treatment of high cholesterol; and Sensipar/Mimpara products for use in the treatment of secondary hyperparathyroidism in CKD patients on dialysis. The companys other marketed products include Kyprolis, a proteasome inhibitor to treat patients with multiple myeloma and small-cell lung cancer; Nplate, a thrombopoietic compound; Vectibix, a human monoclonal antibody; and BLINCYTO for the treatment of patients with Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia. It also develops various products that are in various clinical trials. The company serves pharmaceutical wholesale distributors; and physicians or their clinics, dialysis centers, hospitals, and pharmacies, as well as consumers. It has collaborative agreements with Xencor, Inc.; UCB; Novartis AG; and Bayer HealthCare Pharmaceuticals Inc. Amgen Inc. was founded in 1980 and is headquartered in Thousand Oaks, California.

Analysts: Anadarko Petroleum Corporation (NYSE:APC) Stock Could Go to 108.00

Analysts are weighing in on how Anadarko Petroleum Corporation (NYSE:APC), might perform in the near term. Wall Street analysts have a much less favorable assessment of the stock, with a mean rating of 2.1. The stock is rated as buy by 19 analysts, with 9 outperform and 7 hold rating. The rating score is on a scale of 1 to 5 where 1 stands for strong buy and 5 stands for strong sell.

For the current quarter, the 32.00 analysts offering adjusted EPS forecast have a consensus estimate of $-0.90 a share, which would compare with $0.01 in the same quarter last year. They have a high estimate of $-0.56 and a low estimate of $-1.67. Revenue for the period is expected to total nearly $1.87B from $2.64B the year-ago period.

For the full year, 32.00 Wall Street analysts forecast this company would deliver earnings of -3.46 per share, with a high estimate of $-2.36 and a low estimate of $-4.30. It had reported earnings per share of $-2.00 in the corresponding quarter of the previous year. Revenue for the period is expected to total nearly $7.88B versus 8.70B in the preceding year.

The analysts project the company to maintain annual growth of around -44.29% percent over the next five years as compared to an average growth rate of 8.52% percent expected for its competitors in the same industry.

Among the 32 analysts Data provided by Thomson/First Call tracks, the 12-month average price target for APC is $64.50 but some analysts are projecting the price to go as high as $108.00. If the optimistic analysts are correct, that represents a 95 percent upside potential from the recent closing price of $55.52. Some sell-side analysts, particularly the bearish ones, have called for $42.00 price targets on shares of Anadarko Petroleum Corporation (NYSE:APC).

In the last reported results, the company reported earnings of $0.01 per share, while analysts were calling for share earnings of $-0.51. It was an earnings surprise of 102.00%percent. In the matter of earnings surprises, the term Cockroach Effect is often implied. Cockroach Effect is a market theory that suggests that when a company reveals bad news to the public, there may be many more related negative events that have yet to be revealed. In the case of earnings surprises, if a company is suggesting a negative earnings surprise it means there are more to come.

Anadarko Petroleum Corporation engages in the exploration, development, production, and marketing of oil and gas properties. It operates through three segments: Oil and Gas Exploration and Production; Midstream; and Marketing. The Oil and Gas Exploration and Production segment explores for and produces oil, condensate, natural gas, and natural gas liquids (NGLs). The Midstream segment provides gathering, processing, treating, and transportation services to Anadarko and third-party oil, natural-gas, and NGLs producers, as well as owns and operates gathering, processing, treating, and transportation systems in the United States. The Marketing segment markets oil, natural gas, and NGLs in the United States; oil and NGLs internationally; and anticipated liquefied natural gas production from Mozambique. The companys asset portfolio includes U.S. onshore resource plays in the Rocky Mountains area, the southern United States, the Appalachian basin, and Alaska; the deepwater Gulf of Mexico; and in Algeria, Ghana, Mozambique, Colombia, Cte dIvoire, New Zealand, Kenya, and other countries. As of December 31, 2015, it had approximately 2.1 billion barrels of oil equivalent of proved reserves. Anadarko Petroleum Corporation was founded in 1959 and is headquartered in The Woodlands, Texas.

Analysts: Baxter International Inc (NYSE:BAX) Stock Could Go to 60.00

Analysts are weighing in on how Baxter International Inc (NYSE:BAX), might perform in the near term. Wall Street analysts have a much less favorable assessment of the stock, with a mean rating of 2.9. The stock is rated as buy by 3 analysts, with 0 outperform and 12 hold rating. The rating score is on a scale of 1 to 5 where 1 stands for strong buy and 5 stands for strong sell.

For the current quarter, the 15.00 analysts offering adjusted EPS forecast have a consensus estimate of $0.39 a share, which would compare with $0.19 in the same quarter last year. They have a high estimate of $0.42 and a low estimate of $0.38. Revenue for the period is expected to total nearly $2.51B from $3.89B the year-ago period.

For the full year, 16.00 Wall Street analysts forecast this company would deliver earnings of 1.64 per share, with a high estimate of $1.70 and a low estimate of $1.59. It had reported earnings per share of $1.38 in the corresponding quarter of the previous year. Revenue for the period is expected to total nearly $10.09B versus 9.97B in the preceding year.

The analysts project the company to maintain annual growth of around 11.60% percent over the next five years as compared to an average growth rate of 12.91% percent expected for its competitors in the same industry.

Among the 11 analysts Data provided by Thomson/First Call tracks, the 12-month average price target for BAX is $48.82 but some analysts are projecting the price to go as high as $60.00. If the optimistic analysts are correct, that represents a 31 percent upside potential from the recent closing price of $45.96. Some sell-side analysts, particularly the bearish ones, have called for $43.00 price targets on shares of Baxter International Inc (NYSE:BAX).

In the last reported results, the company reported earnings of $0.19 per share, while analysts were calling for share earnings of $0.95. It was an earnings surprise of -80.00%percent. In the matter of earnings surprises, the term Cockroach Effect is often implied. Cockroach Effect is a market theory that suggests that when a company reveals bad news to the public, there may be many more related negative events that have yet to be revealed. In the case of earnings surprises, if a company is suggesting a negative earnings surprise it means there are more to come.

Baxter International Inc. provides a portfolio of renal and hospital products. Its Renal segment provides products and services to treat end-stage renal disease, irreversible kidney failure, and acute kidney therapies. This segment offers a comprehensive portfolio to meet the needs of patients across the treatment continuum, including technologies and therapies for peritoneal dialysis, in-center hemodialysis (HD), home HD, continuous renal replacement therapy, and additional dialysis services. The Hospital Products segment manufactures intravenous (IV) solutions and administration sets, premixed drugs and drug-reconstitution systems, pre-filled vials and syringes for injectable drugs, IV nutrition products, infusion pumps, inhalation anesthetics, and biosurgery products. This segment also provides products and services related to pharmacy compounding, drug formulation, and packaging technologies. The company sells its products for use in hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors offices, and by patients at home under physician supervision. Baxter International Inc. offers its products through direct sales force, independent distributors or sales agents, drug wholesalers, and specialty pharmacy or other alternate site providers in approximately 100 countries. It has a collaboration agreement with JW Holdings Corporation to co-develop and distribute parenteral nutritional products containing a novel formulation of omega 3 lipids; and agreement with Celerity Pharmaceutical, LLC to develop certain acute care generic injectable premix and oncolytic molecules. The company was founded in 1931 and is headquartered in Deerfield, Illinois.

Analysts: Cadence Design Systems Inc (NASDAQ:CDNS) Stock Could Go to 29.00

Analysts are weighing in on how Cadence Design Systems Inc (NASDAQ:CDNS) , might perform in the near term. Wall Street analysts have a much less favorable assessment of the stock, with a mean rating of 2.4. The stock is rated as buy by 1 analysts, with 2 outperform and 5 hold rating. The rating score is on a scale of 1 to 5 where 1 stands for strong buy and 5 stands for strong sell.

For the current quarter, the 8.00 analysts offering adjusted EPS forecast have a consensus estimate of $0.28 a share, which would compare with $0.27 in the same quarter last year. They have a high estimate of $0.29 and a low estimate of $0.28. Revenue for the period is expected to total nearly $449.54M from $415.88M the year-ago period.

For the full year, 8.00 Wall Street analysts forecast this company would deliver earnings of 1.21 per share, with a high estimate of $1.23 and a low estimate of $1.19. It had reported earnings per share of $1.09 in the corresponding quarter of the previous year. Revenue for the period is expected to total nearly $1.82B versus 1.70B in the preceding year.

The analysts project the company to maintain annual growth of around 9.50% percent over the next five years as compared to an average growth rate of 17.10% percent expected for its competitors in the same industry.

Among the 7 analysts Data provided by Thomson/First Call tracks, the 12-month average price target for CDNS is $25.43 but some analysts are projecting the price to go as high as $29.00. If the optimistic analysts are correct, that represents a 18 percent upside potential from the recent closing price of $24.62. Some sell-side analysts, particularly the bearish ones, have called for $22.00 price targets on shares of Cadence Design Systems Inc (NASDAQ:CDNS) .

In the last reported results, the company reported earnings of $0.27 per share, while analysts were calling for share earnings of $0.24. It was an earnings surprise of 12.50%percent. In the matter of earnings surprises, the term Cockroach Effect is often implied. Cockroach Effect is a market theory that suggests that when a company reveals bad news to the public, there may be many more related negative events that have yet to be revealed. In the case of earnings surprises, if a company is suggesting a negative earnings surprise it means there are more to come.

Cadence Design Systems, Inc. develops, sells, leases, and licenses electronic design automation (EDA) software, emulation and prototyping hardware, verification intellectual property (VIP), and design intellectual property (IP) for semiconductor and electronics systems industries worldwide. It offers functional verification products, including logic verification software that enables customers to coordinate verification activities across multiple teams and various specialists for verification planning and closure; and system design and verification products for hardware-software verification, as well as for system power exploration, analysis, and optimization. The company also provides digital integrated circuit (IC) design products, such as logic design products for chip planning, design, verification, and test technologies and services; physical implementation tools, including place and route, signal integrity, optimization, and double patterning preparation; and signoff products to signoff the design as ready for manufacture by a silicon foundry, as well as design for manufacturing products for use in the product development process. In addition, it offers custom IC design and verification products to create schematic and physical representations of circuits down to the transistor level for analog, mixed-signal, custom digital, memory, and RF designs; and system interconnect design products to develop printed circuit boards and IC packages. Further, the company provides design IP products consisting of pre-verified and customizable functional blocks to integrate into customers system-on-chips; and VIP and memory models for use in system-level verification to model correct behavior of full systems interacting with their environments. Additionally, it offers services related to methodology, education, and hosted design solutions, as well as technical support and maintenance services. The company was founded in 1988 and is headquartered in San Jose, California.

Analysts: Calpine Corp. (NYSE:CPN)

Analysts are weighing in on how Calpine Corporation (NYSE:CPN), might perform in the near term. Wall Street analysts have a much favorable assessment of the stock, with a mean rating of 1.9. The stock is rated as buy by 9 analysts, with 5 outperform and 3 hold rating. The rating score is on a scale of 1 to 5 where 1 stands for strong buy and 5 stands for strong sell.

For the current quarter, the 3.00 analysts offering adjusted EPS forecast have a consensus estimate of $-0.02 a share, which would compare with $0.09 in the same quarter last year. They have a high estimate of $0.11 and a low estimate of $-0.11. Revenue for the period is expected to total nearly $1.29B from $1.44B the year-ago period.

For the full year, 7.00 Wall Street analysts forecast this company would deliver earnings of 0.51 per share, with a high estimate of $0.60 and a low estimate of $0.35. It had reported earnings per share of $1.05 in the corresponding quarter of the previous year. Revenue for the period is expected to total nearly $5.57B versus 6.47B in the preceding year.

The analysts project the company to maintain annual growth of around 5.10% percent over the next five years as compared to an average growth rate of 6.59% percent expected for its competitors in the same industry.

Among the 15 analysts Data provided by Thomson/First Call tracks, the 12-month average price target for CPN is $18.87 but some analysts are projecting the price to go as high as $23.00. If the optimistic analysts are correct, that represents a 62 percent upside potential from the recent closing price of $14.18. Some sell-side analysts, particularly the bearish ones, have called for $15.00 price targets on shares of Calpine Corporation (NYSE:CPN).

In the last reported results, the company reported earnings of $0.09 per share, while analysts were calling for share earnings of $-0.05. It was an earnings surprise of 280.00%percent. In the matter of earnings surprises, the term Cockroach Effect is often implied. Cockroach Effect is a market theory that suggests that when a company reveals bad news to the public, there may be many more related negative events that have yet to be revealed. In the case of earnings surprises, if a company is suggesting a negative earnings surprise it means there are more to come.

Calpine Corporation, a wholesale power generation company, owns and operates natural gas-fired and geothermal power plants in North America. It operates natural gas-fired combustion turbines and renewable geothermal conventional steam turbines. The company sells power, steam, capacity, renewable energy credits, and ancillary services to utilities, independent electric system operators, industrial and agricultural companies, retail power providers, municipalities and other governmental entities, and power marketers, as well as retail commercial, industrial, and residential customers. As of February 5, 2016, it owned and operated 84 power plants, including 1 under construction with an aggregate generation capacity of 27,282 megawatts and 760 megawatts under construction. Calpine Corporation was founded in 1984 and is based in Houston, Texas.

Analysts: Centurylink Inc (NYSE:CTL) Stock Could Go to 42.00

Analysts are weighing in on how Centurylink Inc (NYSE:CTL), might perform in the near term. Wall Street analysts have a much less favorable assessment of the stock, with a mean rating of 2.9. The stock is rated as buy by 3 analysts, with 1 outperform and 10 hold rating. The rating score is on a scale of 1 to 5 where 1 stands for strong buy and 5 stands for strong sell.

For the current quarter, the 16.00 analysts offering adjusted EPS forecast have a consensus estimate of $0.59 a share, which would compare with $0.55 in the same quarter last year. They have a high estimate of $0.62 and a low estimate of $0.57. Revenue for the period is expected to total nearly $4.39B from $4.42B the year-ago period.

For the full year, 16.00 Wall Street analysts forecast this company would deliver earnings of 2.58 per share, with a high estimate of $2.65 and a low estimate of $2.52. It had reported earnings per share of $2.71 in the corresponding quarter of the previous year. Revenue for the period is expected to total nearly $17.58B versus 17.90B in the preceding year.

The analysts project the company to maintain annual growth of around 0.23% percent over the next five years as compared to an average growth rate of 6.44% percent expected for its competitors in the same industry.

Among the 15 analysts Data provided by Thomson/First Call tracks, the 12-month average price target for CTL is $29.60 but some analysts are projecting the price to go as high as $42.00. If the optimistic analysts are correct, that represents a 47 percent upside potential from the recent closing price of $28.52. Some sell-side analysts, particularly the bearish ones, have called for $22.00 price targets on shares of Centurylink Inc (NYSE:CTL).

In the last reported results, the company reported earnings of $0.55 per share, while analysts were calling for share earnings of $0.60. It was an earnings surprise of -8.30%percent. In the matter of earnings surprises, the term Cockroach Effect is often implied. Cockroach Effect is a market theory that suggests that when a company reveals bad news to the public, there may be many more related negative events that have yet to be revealed. In the case of earnings surprises, if a company is suggesting a negative earnings surprise it means there are more to come.

CenturyLink, Inc. provides various communications services to residential, business, wholesale, and governmental customers in the United States. It operates through two segments, Business and Consumer. The company offers high-speed Internet services, which allow customers to connect to the Internet through their existing telephone lines or fiber-optic cables; multi-protocol label switching, a data networking technology to support real-time voice and video; and private line services for the transmission of data between sites. It also provides Ethernet services, including point-to-point and multi-point equipment configurations that facilitate data transmissions across metropolitan areas and wide area networks (WAN); colocation services that enable its customers to install their own information technology (IT) equipment; and managed hosting services comprising cloud and traditional computing, application management, back-up, storage, and other services. In addition, the company offers video entertainment services and satellite digital television; Voice over Internet Protocol, a real-time, two-way voice communication service; and managed services that consist of network, hosting, cloud, and IT services. Further, it provides local calling, long-distance voice, integrated services digital network, WAN, and switched access services; and data integration, which includes the sale of telecommunications equipment and providing network management, installation, and maintenance of data equipment, and the building of proprietary fiber-optic broadband networks. Additionally, the company leases and subleases space in its office buildings, warehouses, and other properties. As of December 31, 2015, it served approximately 6 million high-speed Internet subscribers and 285 thousand television subscribers; and operated 59 data centers in North America, Europe, and Asia. CenturyLink, Inc. was founded in 1968 and is headquartered in Monroe, Louisiana.

Analysts: Halcon Resources Corp (NYSE:HK) Stock Could Go to 5.00

Analysts are weighing in on how Halcon Resources Corp (NYSE:HK), might perform in the near term. Wall Street analysts have a unfavorable assessment of the stock, with a mean rating of 3.4. The stock is rated as buy by 1 analysts, with 0 outperform and 3 hold rating. The rating score is on a scale of 1 to 5 where 1 stands for strong buy and 5 stands for strong sell.

For the current quarter, the 7.00 analysts offering adjusted EPS forecast have a consensus estimate of $0.04 a share, which would compare with $0.10 in the same quarter last year. They have a high estimate of $0.19 and a low estimate of $-0.19. Revenue for the period is expected to total nearly $167.81M from $168.02M the year-ago period.

For the full year, 6.00 Wall Street analysts forecast this company would deliver earnings of 0.48 per share, with a high estimate of $0.75 and a low estimate of $-0.10. It had reported earnings per share of $1.01 in the corresponding quarter of the previous year. Revenue for the period is expected to total nearly $595.73M versus 550.28M in the preceding year.

The analysts project the company to maintain annual growth of around 25.00% percent over the next five years as compared to an average growth rate of 8.52% percent expected for its competitors in the same industry.

Among the 6 analysts Data provided by Thomson/First Call tracks, the 12-month average price target for HK is $1.73 but some analysts are projecting the price to go as high as $5.00. If the optimistic analysts are correct, that represents a 900 percent upside potential from the recent closing price of $0.50. Some sell-side analysts, particularly the bearish ones, have called for $0.40 price targets on shares of Halcon Resources Corp (NYSE:HK).

In the last reported results, the company reported earnings of $0.10 per share, while analysts were calling for share earnings of $-0.10. It was an earnings surprise of 200.00%percent. In the matter of earnings surprises, the term Cockroach Effect is often implied. Cockroach Effect is a market theory that suggests that when a company reveals bad news to the public, there may be many more related negative events that have yet to be revealed. In the case of earnings surprises, if a company is suggesting a negative earnings surprise it means there are more to come.

Halcn Resources Corporation, an independent energy company, engages in the acquisition, production, exploration, and development of onshore oil and natural gas properties in the United States. The company primarily holds interests the Bakken/Three Forks Formations comprising approximately 123,000 net acres of area in North Dakota; and East Texas Eagle Ford Formations covering approximately 92,000 acres of area in Brazos, Burleson, and Robertson counties. As of December 31, 2014, it had estimated proved reserves of approximately 146.8 million barrels of oil equivalent comprising 120.7 million barrels of crude oil, 13.0 million barrels of natural gas liquids, and 78.4 billion cubic feet of natural gas. The company was formerly known as RAM Energy Resources, Inc. and changed its name to Halcn Resources Corporation in February 2012. Halcn Resources Corporation is headquartered in Houston, Texas.

Analysts: Invesco Ltd. (NYSE:IVZ) Stock Could Go to 40.00

Analysts are weighing in on how Invesco Ltd. (NYSE:IVZ), might perform in the near term. Wall Street analysts have a much favorable assessment of the stock, with a mean rating of 1.9. The stock is rated as buy by 7 analysts, with 5 outperform and 4 hold rating. The rating score is on a scale of 1 to 5 where 1 stands for strong buy and 5 stands for strong sell.

For the current quarter, the 15.00 analysts offering adjusted EPS forecast have a consensus estimate of $0.57 a share, which would compare with $0.63 in the same quarter last year. They have a high estimate of $0.59 and a low estimate of $0.53. Revenue for the period is expected to total nearly $854.35M from $936.60M the year-ago period.

For the full year, 16.00 Wall Street analysts forecast this company would deliver earnings of 2.32 per share, with a high estimate of $2.45 and a low estimate of $2.17. It had reported earnings per share of $2.44 in the corresponding quarter of the previous year. Revenue for the period is expected to total nearly $3.47B versus 3.64B in the preceding year.

The analysts project the company to maintain annual growth of around 9.96% percent over the next five years as compared to an average growth rate of 10.60% percent expected for its competitors in the same industry.

Among the 13 analysts Data provided by Thomson/First Call tracks, the 12-month average price target for IVZ is $36.46 but some analysts are projecting the price to go as high as $40.00. If the optimistic analysts are correct, that represents a 35 percent upside potential from the recent closing price of $29.62. Some sell-side analysts, particularly the bearish ones, have called for $32.00 price targets on shares of Invesco Ltd. (NYSE:IVZ).

In the last reported results, the company reported earnings of $0.63 per share, while analysts were calling for share earnings of $0.62. It was an earnings surprise of 1.60%percent. In the matter of earnings surprises, the term Cockroach Effect is often implied. Cockroach Effect is a market theory that suggests that when a company reveals bad news to the public, there may be many more related negative events that have yet to be revealed. In the case of earnings surprises, if a company is suggesting a negative earnings surprise it means there are more to come.

Invesco Ltd. is a publicly owned investment manager. The firm provides its services to retail clients, institutional clients, high-net worth clients, public entities, corporations, unions, non-profit organizations, endowments, foundations, pension funds, financial institutions, and sovereign wealth funds. It manages separate client focused equity, balanced, and fixed income portfolios. The firm also launches equity, fixed income, commodity, multi-asset, and balanced mutual funds for its clients. It launches equity, fixed income, multi-asset, and balanced exchange-traded funds. The firm also launches and manages private funds. It invests in the public equity and fixed income markets across the globe. The firm also invests in alternative markets, such as commodities and currencies. It invests in growth and value stocks of large-cap, mid-cap, and small-cap companies. For the fixed income portion, the firm invests in convertibles, government bonds, municipal bonds, treasury securities, and cash. It also invests in short term and intermediate term bonds, investment grade and high yield bonds, taxable and tax-free bonds, senior secured loans, and structured securities such as asset-backed securities, mortgage-backed securities, and commercial mortgage-backed securities. The firm also employs absolute return, global macro, long/short equity, currencies, commodities, managed futures, and private capital strategies. It employs quantitative analysis to make its investments. The firm was formerly known as Invesco Plc, AMVESCAP plc, Amvesco plc, Invesco PLC, Invesco MIM, and H. Lotery & Co. Ltd. Invesco Ltd. was founded in December 1935 and is based in Atlanta, Georgia with an additional office in Hamilton, Bermuda.